The DOI matches its Crossref record; 215 of the 216 references it cites were found in a registry or an index.
Clinical Applications Involving CNS Gene Transfer
Open accessAbstract
Diseases of the central nervous system (CNS) have traditionally been the most difficult to treat by traditional pharmacological methods, due mostly to the blood-brain barrier and the difficulties associated with repeated drug administration targeting the CNS. Viral vector gene transfer represents a way to permanently provide a therapeutic protein within the nervous system after a single administration, whether this be a gene replacement strategy for an inherited disorder or a disease-modifying protein for a disease such as Parkinson's. Gene therapy approaches for CNS disorders has evolved considerably over the last two decades. Although a breakthrough treatment has remained elusive, current strategies are now considerably safer and potentially much more effective. This chapter will explore the past, current, and future status of CNS gene therapy, focusing on clinical trials utilizing adeno-associated virus and lentiviral vectors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AAV vectors support long-term, non-toxic gene expression for up to 8 years in non-human primates.1–3”
From Characterization of a novel adeno-associated viral vector with preferential oligodendrocyte tropism (2016) · cites this paper as [2]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Foust, K. D., Wang, X., McGovern, V. L., Braun, L., Bevan, A. K., Haidet, A. M., Le, T. T., Morales, P. R., Rich, M. M., Burghes, A. H. M., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1610 · Cited by 688
RetractedIn Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector
Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., & Trono, D. (1996) · Science · doi:10.1126/science.272.5259.263 · Cited by 4,903
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
A Third-Generation Lentivirus Vector with a Conditional Packaging System
Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D., & Naldini, L. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8463-8471.1998 · Cited by 3,341
Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
Cavazzana, M., Hacein‐Bey‐Abina, S., Basile, G. D. S., Gross, F., Yvon, E. S., Nusbaum, P., Selz, F., Hue, C., Dogniaux, S., Casanova, J., et al. (2000) · Science · doi:10.1126/science.288.5466.669 · Cited by 2,685
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo
Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L., & Trono, D. (1997) · Nature Biotechnology · doi:10.1038/nbt0997-871 · Cited by 1,977
A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.-L., Fraser, C. C., Cavazzana-Calvo, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejm200301163480314 · Cited by 1,867
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery
Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L., & Trono, D. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9873-9880.1998 · Cited by 1,815
Research works printed but not linked: 1
- Van Bogaert, 1949, Sur une idiote familiale avec degenerescence sponglieuse de neuraxe (note preliminaire), Acta Neurologica Belgica, 49, 572
Cited by
Sorted by citations
Huntingtin Lowering Strategies for Disease Modification in Huntington’s Disease
Tabrizi, S. J., Ghosh, R., & Leavitt, B. R. (2019) · Neuron · doi:10.1016/j.neuron.2019.01.039 · Cited by 336
Kantor, B., Tagliafierro, L., Gu, J. T., Zamora, M. E., Ilich, E., Grenier, C., Huang, Z. Y., Murphy, S. K., & Chiba‐Falek, O. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.08.019 · Cited by 209
Self-citationAAV-based in vivo gene therapy for neurological disorders
Ling, Q., Herstine, J. A., Bradbury, A. M., & Gray, S. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00766-7 · Cited by 223
Self-citationOrtinski, P. I., O’Donovan, B., Dong, X., & Kantor, B. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.04.002 · Cited by 146
Self-citationDong, W., & Kantor, B. (2021) · Viruses · doi:10.3390/v13071288 · Cited by 162
Self-citationMead, B. P., Mastorakos, P., Suk, J. S., Klibanov, A. L., Hanes, J. S., & Price, R. J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.034 · Cited by 146
Recent progress and considerations for AAV gene therapies targeting the central nervous system
Lykken, E. A., Shyng, C., Edwards, R. J., Rozenberg, A. J., & Gray, S. J. (2018) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-018-9234-0 · Cited by 144
Self-citationTanenhaus, A., Stowe, T., Young, A., McLaughlin, J., Aeran, R., Lin, I. W., Li, J., Hosur, R., Chen, M., Leedy, J., et al. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.037 · Cited by 124
“22 However, as the SCN1A gene (cDNA * 6 kb) exceeds the packaging capacity of AAV (4.7 kb DNA), 23 AAV-mediated gene replacement therapy for SCN1A + DS is not a viable approach.”
InfluentialMicroglia-specific targeting by novel capsid-modified AAV6 vectors
Rosario, A. M., Cruz, P. E., Ceballos‐Diaz, C., Strickland, M. R., Siemienski, Z. B., Pardo, M., Schob, K.-L., Li, A., Aslanidi, G., Srivastava, A., et al. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.26 · Cited by 120
Keiser, M. S., Kordasiewicz, H. B., & McBride, J. L. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv442 · Cited by 117
Gene therapy for neurological disorders: challenges and recent advancements
Peña, S., Iyengar, R., Eshraghi, R. S., Bencie, N., Mittal, J., Aljohani, A., Mittal, R., & Eshraghi, A. A. (2019) · Journal of drug targeting · doi:10.1080/1061186x.2019.1630415 · Cited by 116
Characterization of a novel adeno-associated viral vector with preferential oligodendrocyte tropism
Powell, S. K., Khan, N., Parker, C. L., Samulski, R. J., Matsushima, G., Gray, S. J., & McCown, T. J. (2016) · Gene Therapy · doi:10.1038/gt.2016.62 · Cited by 92
Self-citationLow intensity focused ultrasound: a new prospect for the treatment of Parkinson’s disease
Zhong, Y., Liao, J., Liu, X., Tian, H., Deng, L.-R., & Long, L. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2251145 · Cited by 64
A patient-based model of RNA mis-splicing uncovers treatment targets in Parkinson’s disease
Boussaad, I., Obermaier, C. D., Hanss, Z., Bobbili, D. R., Bolognin, S., Glaab, E., Wołyńska, K., Weisschuh, N., Conti, L. D., May, C., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aau3960 · Cited by 56
AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy
Ising, C., Gallardo, G., Leyns, C. E. G., Wong, C. H., Jiang, H., Stewart, F., Koscal, L. J., Roh, J., Robinson, G. O., Remolina Serrano, J., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20162125 · Cited by 57
Sonoselective transfection of cerebral vasculature without blood–brain barrier disruption
Gorick, C. M., Mathew, A. S., Garrison, W. J., Thim, E. A., Fisher, D. G., Copeland, C. A., Song, J., Klibanov, A. L., Miller, G. W., & Price, R. J. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1914595117 · Cited by 57
Gene suppression approaches to neurodegeneration
Ghosh, R., & Tabrizi, S. J. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0307-1 · Cited by 56
Rittiner, J. E., Moncalvo, M., Chiba‐Falek, O., & Kantor, B. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00148 · Cited by 53
Self-citationAblating N‐acetylaspartate prevents leukodystrophy in a Canavan disease model
Guo, F., Bannerman, P., Mills Ko, E., Miers, L., Xu, J., Burns, T., Li, S., Freeman, E., McDonough, J. A., & Pleasure, D. (2015) · Annals of Neurology · doi:10.1002/ana.24392 · Cited by 52
Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic
Miniarikova, J., Evers, M. M., & Konstantinova, P. S. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.002 · Cited by 43
Rittiner, J. E., Cumaran, M., Malhotra, S., & Kantor, B. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.1035543 · Cited by 42
Self-citationKantor, B., O’Donovan, B., Rittiner, J. E., Hodgson, D., Lindner, N., Guerrero, S., Dong, W., Zhang, A., & Chiba‐Falek, O. (2024) · Nature Communications · doi:10.1038/s41467-024-50515-6 · Cited by 48
Self-citationProduction, Purification, and Quality Control for Adeno-associated Virus-based Vectors
Fripont, S., Marneffe, C., Marino, M., Rincón, M. Y., & Holt, M. G. (2019) · Journal of Visualized Experiments · doi:10.3791/58960 · Cited by 38
Adeno-associated virus and lentivirus vectors: a refined toolkit for the central nervous system
Blessing, D., & Déglon, N. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.08.004 · Cited by 36
Nano‐Oncologicals: A Tortoise Trail Reaching New Avenues
Dacoba, T. G., Anthiya, S., Berrecoso, G., Fernández‐Mariño, I., Fernández‐Varela, C., Crecente‐Campo, J., Teijeiro‐Osorio, D., Torres, F., & Alonso, M. J. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202009860 · Cited by 34
Kantor, B., O’Donovan, B., & Chiba‐Falek, O. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102635 · Cited by 38
Self-citationTiming of Gene Therapy Interventions: The Earlier, the Better
Gray, S. J. (2016) · Molecular Therapy · doi:10.1038/mt.2016.20 · Cited by 30
Self-citationLentivirus-mediated PGC-1α overexpression protects against traumatic spinal cord injury in rats
Hu, J., Lang, Y., Zhang, T., Ni, S., & Lü, H. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.04.031 · Cited by 29
Genetics and gene therapy in Dravet syndrome
Higurashi, N., Broccoli, V., & Hirose, S. (2021) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2021.108043 · Cited by 26
Sponge-mediated lentivirus delivery to acute and chronic spinal cord injuries
Thomas, A. M., Palma, J. L., & Shea, L. D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.02.032 · Cited by 24
Wang, X., Zhuang, W., Fu, W., Wang, X., Lv, E., Li, F., Zhou, S., Rausch, W., & Wang, X. (2018) · Europe PMC (PubMed Central) · Cited by 20
Tagliafierro, L., Ilich, E., Moncalvo, M., Gu, J. T., Sriskanda, A., Grenier, C., Murphy, S. K., Chiba‐Falek, O., & Kantor, B. (2019) · Journal of Visualized Experiments · doi:10.3791/59241 · Cited by 19
Self-citationNowak, I., Madej, M., Secemska, J., Sarna, R., & Strzałka‐Mrozik, B. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071931 · Cited by 18
Leukodystrophy imaging: Insights for diagnostic dilemmas.
Thakkar, R. N., Patel, D., Kioutchoukova, I. P., Al-Bahou, R., Reddy, P., Foster, D. T., & Lucke-Wold, B. (2024) · Medical Sciences · doi:10.3390/medsci12010007 · Cited by 17
Stacking up CRISPR against RNA i for therapeutic gene inhibition
Haussecker, D. (2016) · FEBS Journal · doi:10.1111/febs.13742 · Cited by 16
New Tools for Epilepsy Therapy
Falcicchia, C., Simonato, M., & Verlengia, G. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00147 · Cited by 17
Viral Vector-Based Gene Therapy for Epilepsy: What Does the Future Hold?
Bettegazzi, B., Cattaneo, S., Simonato, M., Zucchini, S., & Soukupovà, M. (2023) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-023-00687-6 · Cited by 17
Gene therapy of adeno‐associated virus ( AAV ) vectors in preclinical models of ischemic stroke
Wang, J., Zhu, M., Sun, J., Feng, L., Yang, M., Sun, B., & Mao, L. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14392 · Cited by 14
Buckinx, R., & Timmermans, J. (2016) · Histochemistry and Cell Biology · doi:10.1007/s00418-016-1496-6 · Cited by 14
Hypothalamic leptin gene therapy reduces body weight without accelerating age-related bone loss
Turner, R. T., Dube, M. G., Branscum, A. J., Wong, C. P., Olson, D. A., Zhong, X. S., Kweh, M. F., Larkin, I. V., Wronski, T. J., Rosen, C. J., et al. (2015) · Journal of Endocrinology · doi:10.1530/joe-15-0280 · Cited by 14
Nanoparticle-based Gene Therapy for Neurodegenerative Disorders
Ereej, N., Hameed, H., Khan, M. A., Faheem, S., & Hameed, A. (2024) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575301011240407082559 · Cited by 14
Targeted miRNA Delivery in Epilepsy: Mechanisms, Advances, and Therapeutic Potential
Shyam, M., Bm, O., Srirangan, P., Nivedita, N., & Prince, S. E. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10436-z · Cited by 13
Epigenome Editing in the Brain
Bashtrykov, P., & Jeltsch, A. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-53889-1_21 · Cited by 12
Uchitel, J., Kantor, B., Smith, E. C., & Mikati, M. A. (2020) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2020.04.010 · Cited by 11
Self-citationSCN1A as a therapeutic target for Dravet syndrome
Myers, K. A. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2230364 · Cited by 11
Production, Purification, and Quality Control for Adeno-associated Virus-based Vectors
Fripont, S., Marneffe, C., Marino, M., Rincón, M. Y., & Holt, M. G. (2019) · Journal of Visualized Experiments · doi:10.3791/58960-v · Cited by 10
The mRVG‐9R peptide as a potential therapeutic vector to the central nervous system cells
Villa‐Cedillo, S. A., Soto‐Domínguez, A., Rodríguez‐Rocha, H., García‐García, A., Loera‐Arias, M. D. J., Rivera-Chávez, L. F., Acosta-Espinoza, E. J., Valdés, J., Zavala-Flores, L. M., Montes‐de‐Oca‐Luna, R., et al. (2019) · Cell Biology International · doi:10.1002/cbin.11161 · Cited by 9
Rolfes, S., Munro, D. A. D., Lyras, E. M., Matute, E., Ouk, K., Harms, C., Böttcher, C., & Priller, J. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105024 · Cited by 8
Hosseininia, S. M., Rostami, F., Delphi, L., Ghasemzadeh, Z., Kouhkan, F., & Rezayof, A. (2023) · Experimental Neurology · doi:10.1016/j.expneurol.2023.114560 · Cited by 8
Borlongan, C., Suárez-Meade, P., Carvajal, H. G., Yasuhara, T., Tajiri, N., & Date, I. (2015) · Brain Circulation · doi:10.4103/2394-8108.172884 · Cited by 7
Selective targeting of striatal parvalbumin-expressing interneurons for transgene delivery
Azevedo, M. D., Sander, S., Jeanneret, C., Olfat, S., & Tenenbaum, L. (2021) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2021.109105 · Cited by 7
Gene Therapy for Rett Syndrome: Prospects and Challenges
Gadalla, K. K. E., Ross, P. D., Hector, R. D., Bahey, N. G., Bailey, M. E. S., & Cobb, S. (2015) · Future Neurology · doi:10.2217/fnl.15.29 · Cited by 7
Kantor, B., Duke, L. C., & Bhide, P. G. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102786 · Cited by 6
Self-citationRiboflavin transporter deficiency: AAV9-SLC52A2 gene therapy as a new therapeutic strategy
Mei, C., Magliocca, V., Chen, X., Massey, K., Gonzalez-Cordero, A., Gray, S. J., Tartaglia, M., Bertini, E., Corti, S. P., & Compagnucci, C. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1523773 · Cited by 6
Self-citationGene Therapy Methods and Their Applications in Neurological Disorders
Li, M., & Snider, B. J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809813-4.00001-6 · Cited by 6
Kantor, B., O’Donovan, B., Rittiner, J. E., Hodgson, D., Lindner, N., Guerrero, S., Dong, W., Zhang, A., & Chiba‐Falek, O. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.14.536951 · Cited by 5
Self-citationWang, J.-C., Ding, S., He, Z.-H., Huang, J., Weng, W., Gao, Y.-W., Jiang, J., Lin, Y., & Feng, J. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115285 · Cited by 3
Meng, Y., Liu, H., Bian, N., Gong, J., Zhong, X., Huang, C., Liang, W., & Xu, H. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6505 · Cited by 2
Lentiviral vectors as the delivery vehicles for transduction into iPSCs
Kantor, B., & Chiba‐Falek, O. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85766-6.00005-x · Cited by 3
Self-citationA Brief Review of Viral Delivery Systems for Bone Tissue Engineering
Nguyen, A. T., Pham, D., Nguyen, V., Shen, J., Scott, M., Lévi, B., & James, A. W. (2014) · International Journal of Orthopaedics · doi:10.6051/ijo.v1i4.974 · Cited by 2
Mir, M. Y., Seh, B. A., Rafiq, K., & Légrádi, Á. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062845 · Cited by 1
Viral Gene Therapy for Central Nervous System Diseases
Yadav, V. N., Castro, M. G., & Lowenstein, P. R. (2016) · Springer eBooks · doi:10.1007/978-3-319-33189-8_15 · Cited by 1
Viral Vectors for Studying Drug-Seeking Behavior
Martínez-Rivera, A., Burgdorf, C. E., & Rajadhyaksha, A. M. (2020) · Neuromethods · doi:10.1007/978-1-0716-1146-3_12 · Cited by 1
Antyborzec, I. (2016) · Dublin City University Open Access Institutional Repository (Dublin City University)
Virus-mediated Delivery of the Fmr1 Gene as a Tool for the Treatment of Fragile X Syndrome
Moghaddam, S. G. (2016) · TSpace (University of Toronto)
Strategies for Restoring Vision by Transducing a Channelrhodopsin Gene into Retinal Ganglion Cells
Tomita, H., & Sugano, E. (2017) · Cambridge University Press eBooks · doi:10.1017/9781107281875.028
Tomasiewicz, H. C., Kocharian, G., & Kaplitt, M. G. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-805353-9.00030-9
Childhood Neurodegenerative Disorders
Nair, L. D. V. (2018) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-5225-5282-6.ch018
Gene therapy in the treatment of retinal dystrophies
Hernández, L. Á., Abril, G. T. T., & Calderón, J. L. H. (2018) · Ciencia y Tecnología para la Salud Visual y Ocular · doi:10.19052/sv.5078
Li, H., Jiang, R. Y., Tang, Y. J., Ling, C., Liu, F., & Xu, J. J. (2024) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30659
O’Donovan, B., Rittiner, J. E., Upadhya, S., Hodgson, D., Kantor, B., & Chiba‐Falek, O. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.16.659948
Self-citationKumar, V., Kakoty, V., & Wadhwa, P. K. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-05901-0 · Cited by 1
O’Donovan, B., Rittiner, J. E., Upadhya, S., Hodgson, D., Kantor, B., & Chiba‐Falek, O. (2026) · Neurotherapeutics · doi:10.1016/j.neurot.2026.e01049
Self-citationRashad, M. S., Mittal, A., Chirasani, S., Kim, J., Rawson, C. D., Lucke-Wold, B. P., Karsy, M. J., & Pahlevani, M. (2026) · Journal of Molecular Pathology · doi:10.3390/jmp7030029
Metadata
- Authors
- Kantor, B., McCown, T., Leone, P., & Gray, S. J.
- Affiliations
- University of South Carolina (US)
- University of North Carolina at Chapel Hill (US)
- Rowan University (US)
- Corresponding author
- Gray, Steven J.
- Venue
- Advances in Genetics
- Publisher
- Elsevier
- Published
- 2014
- Volume
- 87
- Pages
- 71-124
- ISSN
- 0065-2660 (ISSN-L)
- PMC
- PMC4518844
- OpenAlex
- W2214048374
- Cited by
- 74
- References
- 216
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 4 · 2023: 8 · 2022: 2 · 2021: 5 · 2020: 6 · 2019: 6 · 2018: 10 · 2017: 5 · 2016: 10 · 2015: 7 · 2014: 1
- FWCI
- 19.65
- Type
- book chapter
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Advances in genetics (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Neurological Disorders and Stroke (P30NS045892, R01NS087175)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- central nervous system gene therapy, adeno-associated virus vectors, lentiviral vectors, blood-brain barrier, gene replacement therapy, Parkinson's disease, disease-modifying therapy, clinical trials
- MeSH terms
- Dependovirus, Central Nervous System Diseases, Genetic Vectors, Humans, Genetic Therapy, Lentivirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
